Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novasep Appoints President and CEO

Published: Thursday, June 27, 2013
Last Updated: Thursday, June 27, 2013
Bookmark and Share
Novasep announces the appointment of Michel Spagnol as President and CEO of the company, effective from 25 June 2013.

He will succeed Patrick Glaser, who after three years at Novasep in France, has decided to return to the USA. Michel Spagnol joins Novasep from Shasun, where he was President and Chief Technology Officer. He is a proven business leader with core expertise in leading contract manufacturing of active pharmaceutical ingredients and, more broadly, strong experience in using and developing innovative technologies to address needs of customers in fine chemicals and life sciences fields. Prior to Shasun Michel Spagnol spent his career at Rhodia in Lyon and Cranbury (NJ, USA) where he progressed first in technical R&D leadership roles and subsequently transitioned to business development as a Sales and Marketing Vice President of Rhodia Pharma Solutions.

Over the past months Novasep’s growth has gained momentum with significant new investments in Mourenx (France), to build the world’s largest chromatography plant dedicated to the pharmaceutical industry, in Le Mans (France) to expand manufacturing capabilities of cutting-edge anti-cancer therapies and in Shanghai (China) to better serve its clients in Asia. Roger-Marc Nicoud, Founder and Non-Executive Chairman of the Board of Novasep, said: “We are delighted to welcome Michel Spagnol to Novasep as CEO.His track record in delivering customer driven solutions, his international and scientific background coupled with his extensive management experience and longstanding knowledge and relationships in the pharmaceutical industry will be strong assets for the Company. He has all the qualities required to consolidate and accelerate Novasep’s development. On behalf of the Board, I would like to thank Patrick Glaser for his contributions as the CEO of the Company and accomplishments as Head of Novasep Synthesis. Over the past years, Novasep has grown significantly under his leadership, and he has developed a solid foundation for Michel Spagnol to build upon.”

Michel Spagnol, new CEO, declared: “Novasep is a world leader in purification technologies with differentiated capabilities in hazardous chemistry and high potency chemistry and is well positioned to serve the pharmaceutical, fine chemical, bio-pharma and industrial biotech industries. I am very pleased to be given the opportunity to lead the Company. I am looking forward to working closely with all my new colleagues. Novasep is on the right track for continued growth and expansion with promising projects which will enable us to continue delivering value-added solutions for our global customers.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novasep and instrAction Enter into a Worldwide Strategic Alliance for Non-Chiral Chromatography
Combination of instrAction and Novasep know-how sets a new standard for small molecule purification processes for the life science industries.
Tuesday, July 20, 2010
Novasep Acquires Bioprocess Development Specialist and Contract Manufacturer Henogen
Acquisition of upstream processing capabilities and services enables Novasep to offer full-range of biomanufacturing solutions.
Wednesday, July 08, 2009
Scientific News
Combining Chemotherapy With Immune-Blocking Drug Could Stop Cancer Growing Back
Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people.
Researchers Pioneer Use of Capsules to Save Materials
Wax capsule delivery systems can simplify a wide range of chemistry transformations.
Photoredox Catalyst Unlocks New Pathways for Nickel Chemistry
Using a light-activated catalyst, researchers have unlocked a new pathway in nickel chemistry to construct carbon-oxygen (C-O) bonds that would be highly valuable to pharmaceutical and agrochemical industries.
Scientists Determine How Antibiotic Gains Cancer-Killing Sulfur Atoms
In a discovery with implications for future drug design scientists have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.
Familiar Drugs May Block Ebola Virus Infection
A well-known class of molecules, many of which are already in use therapeutically, may be able to block the Ebola virus’s entry into cells and halt the disease in its tracks, according to researchers at the University of Illinois at Chicago.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Common Class of ‘Channel Blocking’ Drugs May Find a Role in Cancer Therapy
Discoveries in fruit flies prompt unusual treatment of patient with metastatic disease.
Common Medications Could Delay Brain Injury Recovery
Drugs used to treat common complaints could delay the recovery of brain injury patients according to research by University of East Anglia (UEA) and University of Aberdeen scientists, published today in Brain Injury.
Scientists Make Strides in Therapy Preventing Addiction Relapse
Single Injection of Drug Candidate Prevents Meth Relapse in Animal Models.
New Clot-Busting Treatments Target Number One Killer
Australian researchers funded by the National Heart Foundation are a step closer to a safer and more effective way to treat heart attack and stroke via nanotechnology.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!